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ABSTRACT
Glioblastoma (GBM), a Grade IV brain tumour, is a well-known radioresistant cancer. To investigate one of the
causes of radioresistance, we studied the capacity for potential lethal damage repair (PLDR) of three altered
strains of GBM: T98G, U87 and LN18, irradiated with various ions and various levels of linear energy transfer
(LET). The GBM cells were exposed to 12C and 28Si ion beams with LETs of 55, 100 and 200 keV/μm, and
with X-ray beams of 1.7 keV/μm. Mono-energetic 12C ions and 28Si ions were generated by the Heavy Ion
Medical Accelerator at the National Institute of Radiological Science, Chiba, Japan. Clonogenic assays were used
to determine cell inactivation. The ability of the cells to repair potential lethal damage was demonstrated by
allowing one identical set of irradiated cells to repair for 24 h before subplating. The results show there is deﬁn-
ite PLDR with X-rays, some evidence of PLDR at 55 keV/μm, and minimal PLDR at 100 keV/μm. There is no
observable PLDR at 200 keV/μm. This is the ﬁrst study, to the authors’ knowledge, demonstrating the capability
of GBM cells to repair potential lethal damage following charged ion irradiations. It is concluded that a GBM’s
PLDR is dependent on LET, dose and GBM strain; and the more radioresistant the cell strain, the greater the
PLDR.
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INTRODUCTION
In this study, we examined the capability of glioblastoma (GBM)
cells to repair potential lethal damage induced by charged ion beam
radiation of various levels of linear energy transfer (LET). The
current standard of care for GBM patients is surgery, where pos-
sible, followed by radiation therapy plus concomitant and adjuvant
chemotherapy [1]. Unfortunately, GBM is a highly aggressive and
persistent hypoxic tumour, it often recurs and patients generally
© The Author(s) 2018. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
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survive less than 2 years after initial diagnosis. GBM is known to be
radioresistant to photon therapy. Radioresistant tumours have the
ability to repair DNA damage induced by photon irradiation or by
other low-LET irradiation [2, 3]. Possible causes of treatment failure
have been proposed: hypoxic portions of tumour; stem (tumour-ini-
tiating) cells; genetic alterations; and many other factors [4–10]. To
overcome radioresistance, new advances and improved radiotherapy
strategies have been described [4, 7]. A potential alternative therapy
to overcome radioresistance in GBM is charged ion radiotherapy.
Charged ion radiations are forms of densely ionizing radiation with
high LET, which are less dependent on oxygen for cell inactivation,
are less affected by variation in cell cycle–related radiosensitivity,
have a higher relative biological effectiveness (RBE) than X-rays
[11], and which are less affected by the ‘5 Rs’ of fractionated radio-
therapy (repair, redistribution, reoxygenation, repopulation and
radiosensitivity) [12].
The three categories of radiation damage produced by ionizing
radiations, as described by Hall et al. [13, 14], are lethal damage
(LD), sublethal damage (SD) and potentially lethal damage (PLD).
Lethal damage is irreversible and irreparable, leading to cell death.
Under normal circumstances, sublethal damage can be repaired in a
matter of hours when no additional sublethal damage is added (e.g.
due to a second dose of radiation) that could lead accumulatively to
lethal damage [15, 16]. This type of damage has been taken advan-
tage of by using fractionated treatments in radiotherapy [15, 16].
Potential lethal damage under normal circumstances can cause cell
death, but may be prevented, and is inﬂuenced by appropriate post-
irradiation environmental conditions, such as delayed subculture of
irradiated cells, incubation at suboptimal temperature, minimal
medium, or treatment with inhibitors of protein synthesis [3, 14,
17–20]. In other words, when the PLD is not repaired, it is lethal.
Potential lethal damage repair (PLDR) has been observed in in vivo
and in vitro experiments with radiation and chemotherapeutic drugs
[18, 21–23]. This repair takes place post irradiation when cells are
allowed time to repair instead of being allowed to proliferate
(through to mitosis/division). Hence, PLDR affects the radiosensi-
tivity of cells and the radiocurability of treated tumours. The con-
cept of PLDR was ﬁrst reported by Phillips and Tolmach [17]
through observation of repair of irradiated HeLa S3 cells in the plat-
eau phase in vitro.
Plateau phase in vitro cultures possess certain characteristics of
tumours in vivo in which a large proportion of the tumour is in G1
or G0 phase [18–20]. Clonogenic assay has been employed to study
PLDR of various types of cell lines irradiated with X-rays, but lim-
ited studies have been carried out on GBM [3, 18–20, 24, 25].
Other methods such as kinetics and ﬁdelity of chromosome rejoin-
ing and gene expression have also been used to demonstrate PLDR
[26, 27].
The ability of cells to repair PLD with high-LET radiation have
been investigated using neutrons [14, 28, 29], α-particles [30], 12C
[31] and 4He ions [32, 33]. Differences in the results following neu-
tron irradiation have been reported. No PLDR was detected by Hall
and Kraljevic, who irradiated Chinese hamster cells [14], or by
Shipley et al. [28], irradiating Lewis lung carcinoma cells in situ with
fast neutrons. Conversely, Rasey et al. [29] reported substantial
PLDR in plateau-phase EMT-6 tumour cells. No PLDR was
detected by Raju et al. after exposure of Chinese hamster cells to
α-particles produced from plutonium 238Pu [30]. Guichard et al.
[32], using 645 MeV 4He ions in the middle of the spread-out
Bragg peak (SOBP), reported comparable PLDR with γ-irradiation
on EMT6 cells in vivo and in vitro. In addition, with extended-
Bragg-peak 4He ions, compared with γ-rays Ward et al. noted less
PLDR in embryonic survival Sprague-Dawley rats when irradiated
on the ﬁfth and sixth days of gestation [33]. Furthermore, Wheeler
et al. [31] observed that the extent of PLDR in 9 L tumour cells
irradiated in situ with SOBP 12C ions was virtually identical to that
observed after X-ray irradiation. In this study, we aimed to ascertain
the PLDR of a number of different GBM strains following irradi-
ation with various ion species and levels of LET.
MATERIALS AND METHODS
Cell lines and cell maintenance
Three human Grade IV glioblastoma cell lines (T98G, U87 and
LN18) were used in this study. The T98G cells were a gift from Mick
Woodcock, Gray Institute for Radiation Oncology and Biology,
Oxford, UK; the U87 cells were obtained from the Health Protection
Agency Culture Collections (HPACC, Wiltshire, UK), and the LN18
cells were obtained from the American Type Culture Collection
(ATCC, Middlesex, UK). All the cell lines were conﬁrmed Mycoplasma
free using Lonza MycoAlert® Mycoplasma Detection Assay.
The cell lines were individually maintained in 75 cm2 plastic ﬂasks
(T75 BD FalconTM 353 084) in Eagle’s Minimum Essential Medium
(MEM: Nissui Pharmaceutical Co. Ltd, Tokyo) supplemented with 10%
fetal bovine serum (FBS: Hyclone, Thermo Scientiﬁc, USA) in a humidi-
ﬁed 95% air/5% CO2 incubator at 37°C. Cells were subcultured from a
T75 plastic ﬂask by rinsing in calcium- and magnesium-free phosphate-
buffered saline (PBS) and exposed to 0.2% trypsin solution containing
0.5mM EDTA. Cell numbers were determined by Coulter Counter. For
all experiments, 3 × 105 cells for each cell line were inoculated into a
25 cm2 plastic ﬂask (T25 BD Falcon 353014) for each dose point, 3 days
before irradiation of the cells (~85–90% in the conﬂuent stage). The
medium was changed on the day of radiation. At least two independent
tests were performed using X-rays, each ion species and each LET.
Irradiations
Cells were irradiated with 12C (135 MeV/n, LET 100 keV/μm) and
28Si (490 MeV/n, LET 55 and 200 keV/μm) monochromatic beams
accelerated at the HIMAC/NIRS, Chiba, Japan. Although the car-
bon ion is the main heavy ion used for medical treatment, previous
studies using neon, helium and silicon ions have been carried out,
and silicon ions are considered to be a potential ion [34, 35] for
radioresistant hypoxic tumours, of which GBM is one. Silicon ions
were once deemed to be of potential signiﬁcance in the treatment
for brain cancer (hypoxic tumours), not only for biological reasons
(RBE 3–4 depending on location of peak, LET and dose fraction
size) and dose localization advantages, but also for its oxygen
enhancement ratio (OER). It has been shown that the magnitude of
the OER decreases progressively as the atomic number and LET of
the accelerated ion species increase [34, 35]. However, with silicon
ions it has not yet been possible to prove or disprove their virtues
in clinical therapy for hypoxic tumours, and indeed few institutes
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could provide such beams compared with the number able to use
carbon ion beam therapy. As silicon is a heavy ion, fragmentations
should be taken into consideration and reduced as far as is practic-
ally possible to emphasize its depth–dose effectiveness and oxygen
gain factor [35]. However, given silicon radiotherapy has been pro-
posed and is under study as a potential ion, it has been included in
this work. Clinically, SOBPs are used for treatment based on the
tumour size and shape. However, for in vitro cells, mono-energetic
beams are more appropriate for studies as they are mono-layered
and the dose average is homogenous. The LETs chosen for silicon
ion were based on the entrance (plateau) and peak positions of the
ion Bragg peak, two points on the depth–dose curve of clinical rele-
vance. For carbon ions, 100 keV/μm was deemed to be highly cyto-
toxic for GBM cells. Further, the particles were chosen for both
their potential as clinically feasible ions and also their beam time
availabilities, which could be assumed to be approximately equiva-
lent to any particles with the same LET [although there are some
differences based on the atomic number of the particle and its radial
energy distributions around the trajectory of the heavy charged par-
ticle (track-structure effects in cell killing) and its microdosimetry].
To change the energy of the beams, Lucite absorbers of different
thicknesses were used. A range of average absorbed dose was used,
depending on the LET employed. The details of the HIMAC beam
delivery system, physical characteristics, biological irradiation proce-
dures and dosimetry have been described by Kanai et al. and
Torikoshi et al. [36, 37]. For comparison with photons, a 200 kVp
X-ray (20 mA) beam ﬁltered with 0.5 mm Cu and 0.5 mm Al
(TITAN 320 irradiator; Ge Inspection Technologies Shimadzu,
Japan) was used, delivering doses at a dose-rate of 1.00 Gy/min ±
0.02. All the irradiations were carried out at room temperature. The
dose-rate of all ion beams was ~3 Gy/min.
For the ions, fragmentations were taken into consideration and
applied to convert particle ﬂuence (Φ) to absorbed dose as
described in [38, 39]:
( ) = × × ( μ )
× Φ ( )
( )
−Absorbed Dose Gy 1.6021 10 LET keV/ m
1/cm
1
9
2
Cell survival assay
The surviving fraction (SF) was measured using the colony forma-
tion assay to assess reproductive death. Two identical sets of plateau
phase GBM cells in T25 ﬂasks (Set A and B) were irradiated at the
same time. Immediately after irradiation, the Set A T25 ﬂasks were
placed in the incubator in a humidiﬁed 95% air/5% CO2 incubator
at 37°C for 24 h. For Set B T25 ﬂasks, immediately post irradiation,
the cells were removed from the T25 ﬂasks and inoculated into trip-
licate 60 mm plastic dishes (Falcon 353002) to produce 60–70 col-
onies per dish. The cells were counted using a Coulter Counter
(Coulter Electronics Ltd, Japan, Tokyo). Set A T25 ﬂasks were
delayed in plating out for 24 h in triplicate 60 mm plastic dishes to
allow for repair of the potential lethal damages induced. The plating
efﬁciency (PE) for T98G was 50–60%, for U87 it was 10–15% and
for LN18 it was 85–95%. Although U87 had a low PE, ~40 colonies
survived post ≤4 Gy dose with LET of 100–200 keV/μm. After 14
days’ incubation, colonies were ﬁxed with 20% methanol and
stained with 0.2% crystal violet. Triplicate dishes of each dose point
colony consisting of more than 50 cells were counted under a
stereomicroscope. The SF at each dose point was determined as the
ratio of live colonies in the treated dish relative to the the number
in the untreated/control. The mean values and standard deviations
of triplicate samples were counted with error propagation.
The plateau phase of the cells was based on the 85–90% con-
ﬂuency of the cells in the T25 ﬂasks. Flow cytometry of 10 000 cells
was performed on both immediate plating (IP) and delayed plating
(DP) cells to determine their stage in the cell cycle. For example, IP
cells for LN18 using 100 keV/μm were 74–78% at plateau phase
and DP (post 24 h) cells were 74 to 68% for control, 0.2 Gy and
0.4 Gy and approximately 59–52% for the other dose points (data
are not shown).
Data analysis
The SF data were obtained from the mean of at least two independ-
ent experiments and ﬁtted by a least squares Linear Quadratic (LQ)
Model equation:
= (−α − β ) ( )S exp D D , 22
where S is the SF and D is the absorbed dose in gray. The α param-
eter describes the linear component of the curve, and the β compo-
nent describes the quadratic portion of the curve. Doses were
calculated from particle ﬂuence and the dose-averaged LET values
by Equation (1), and the results are presented in Table 1. The α
and β values are determined by minimizing the sum of squares cal-
culated by Equation (2). The α/β ratio is the point at which linear
cell kill is equivalent to quadratic cell kill.
RBE is deﬁned as the ratio of a photon dose (Dγ) to a corre-
sponding ion dose (DI) yielding the same biological effect:
= ( )γRBE D /D 3I
Ratio of potential lethal damage repair
PLDR time is deﬁned as the interval between irradiation and subcul-
ture [20]. The PLDR ratio is the SF of DP (R) divided by the SF
of IP (R0) at a single dose. [3, 40]. The PLDR ratio reveals the cap-
ability of the cells for repairing PLD.
= ( )
( )
( )PLDR ratio SF R
SF R
4
0
The extent of PLDR was divided into four levels; deﬁnite
(PLDR ratio of ≥ 2.0), some evidence (PLDR ratio of ≥ 1.3), min-
imal (1.0 < PLDR < 1.3) and no evidence (PLDR ≤ 1.0). RBE10 is
the ratio of absorbed dose required to reduce the SF to 10% for the
ion beam irradiations relative to X-rays. RBE2 Gy is the SF plotted at
RBE2 Gy for ion beam irradiations as compared with RBE2 Gy for
X-rays. The SF graphs, α and β parameters and RBE were plotted/
obtained using KaleidaGraph by Synergy software (version 3.5).
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RESULTS
The results presented are the means of at least two independent
experiments, and the error bars in the survival curves (SCs)
represent the standard deviations (SDs). Figures 1 to 4 (Panels A–C)
show SC versus dose for T98G, U87 and LN18 from irradiations
with LET of 1.7, 55, 100 and 200 keV/μm. Table 1 summarizes the
PLDR effects of the three GBM cell lines α, β, α/β ratio, D10, and
RBE at 10% and 2 Gy [with SD for LET and standard error of means
(SEM) for the other parameters]. Recovery PLDR ratios of the three
GBM strains, the doses and the LETs are summarized in Table 2.
Table 1. IP and DP values of α, β, α/β ratio, D10, and RBE10 and RBE2 Gy of T98G, U87 and LN18 for irradiations with LET
of 1.7, 55, 100 and 200 keV/μm
T98G α β D10 D10 D10 2 Gy
Ions LET (Gy–1) (Gy–2) (Gy) RBE α/β (Gy) RBE
200kVp-IP 1.7 ± 0.02 0.049 ± 0.001 0.109 ± 0.009 4.57 ± 0.023 1.00 ± 0.005 0.45 1.00 ± 0.001
200kVp-DP 1.7 ± 0.02 0.226 ± 0001 0.039 ± 0.001 5.33 ± 0.001 0.86 ± 0.001 5.80 1.06 ± 0.001
28Si 490-IP 55.0 ± 0.06 0.451 ± 0.058 0.213 ± 0.009 2.43 ± 0.027 1.88 ± 0.020 2.12 2.37 ± 0.012
28Si 490-DP 55.0 ± 0.06 0.327 ± 0.004 0.202 ± 0.001 2.65 ± 0.002 1.72 ± 0.001 1.62 1.81 ± 0.001
12C 135-IP 100 ± 1.77 0.935 ± 0.010 0.025 ± 0.004 2.32 ± 0.003 1.97 ± 0.002 37.4 3.55 ± 0.010
12C 135-DP 100 ± 1.77 0.821 ± 0.006 0.062 ± 0.001 2.37 ± 0.016 1.93 ± 0.013 13.2 2.85 ± 0.009
28Si 490-IP 200 ± 3.12 0.791 ± 0.004 0.095 ± 0.001 2.25 ± 0.045 2.03 ± 0.040 8.33 3.17 ± 0.026
28Si 490-DP 200 ± 3.12 1.026 ± 0.007 0.055 ± 0.001 2.07 ± 0.035 2.22 ± 0.038 18.7 3.49 ± 0.021
U87 α β D10 D10 D10 2 Gy
Ions LET (Gy–1) (Gy–2) (Gy) RBE α/β RBE
200kVp-IP 1.7 ± 0.02 0.157 ± 0.006 0.068 ± 0.004 4.81 ± 0.078 1.00 ± 0.016 2.31 1.00 ± 0.001
200kVp-DP 1.7 ± 0.02 0.248 ± 0.004 0.034 ± 0.001 5.35 ± 0.009 0.90 ± 0.001 7.29 1.03 ± 0.001
28Si 490-IP 55.0 ± 0.06 0.515 ± 0.001 0.069 ± 0.001 3.15 ± 0.004 1.53 ± 0.002 7.46 2.00 ± 0.004
28Si 490-DP 55.0 ± 0.06 0.497 ± 0.002 0.034 ± 0.003 3.70 ± 0.005 1.30 ± 0.002 14.6 1.70 ± 0.003
12C 135-IP 100 ± 1.77 1.102 ± 0.101 0.039 ± 0.038 2.27 ± 0.034 2.12 ± 0.032 28.3 3.84 ± 0.011
12C 135-DP 100 ± 1.77 1.039 ± 0.004 0.033 ± 0.002 2.40 ± 0.002 2.00 ± 0.002 31.5 3.36 ± 0.008
28Si 490-IP 200 ± 3.12 1.079 ± 0.015 0.014 ± 0.003 2.05 ± 0.047 2.35 ± 0.054 77.1 3.72 ± 0.021
28Si 490-DP 200 ± 3.12 1.138 ± 0.049 0.025 ± 0.019 1.98 ± 0.020 2.43 ± 0.025 45.5 3.64 ± 0.006
LN18 α β D10 D10 D10 2 Gy
Ions LET (Gy–1) (Gy–2) (Gy) RBE α/β RBE
200kVp-IP 1.7 ± 0.02 0.316 ± 0.001 0.076 ± 0.001 3.81 ± 0.010 1.00 ± 0.004 4.16 1.00 ± 0.001
200kVp-DP 1.7 ± 0.02 0.355 ± 0.003 0.045 ± 0.001 4.22 ± 0.020 0.90 ± 0.005 7.89 0.98 ± 0.001
28Si 490-IP 55.0 ± 0.06 0.642 ± 0.001 0.105 ± 0.001 2.54 ± 0.001 1.50 ± 0.001 6.11 1.64 ± 0.004
28Si 490-DP 55.0 ± 0.06 0.592 ± 0.002 0.056 ± 0.001 3.02 ± 0.010 1.26 ± 0.004 10.6 1.50 ± 0.004
12C 135-IP 100 ± 1.77 1.079 ± 0.002 0.052 ± 0.001 1.95 ± 0.001 1.95 ± 0.002 20.8 2.40 ± 0.002
12C 135-DP 100 ± 1.77 0.941 ± 0.010 0.079 ± 0.003 2.09 ± 0.001 1.82 ± 0.001 11.9 2.27 ± 0.001
28Si 490-IP 200 ± 3.12 1.126 ± 0.016 0.011 ± 0.010 2.00 ± 0.016 1.91 ± 0.017 102 2.42 ± 0.001
28Si 490-DP 200 ± 3.12 1.205 ± 0.002 0.006 ± 0.001 1.89 ± 0.001 2.00 ± 0.001 201 2.72 ± 0.002
LET error = SD, and for other parameters = SEM; IP = immediate plating; DP = 24 h delayed plating.
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Effects of potential lethal damage repair on survival
curves
Our results demonstrated that the PLDR effects showed a minimal
change in the shoulder of the SF curve with X-rays, but a signiﬁcant
increase in the gradient of the slope from 4 Gy onwards (Fig. 1).
For irradiations with LET of 55 keV/μm, T98G, U87 and LN18
cells showed a change in the slope after 2 Gy (Fig. 2). There was lit-
tle change in the slope of PLDR for irradiations with LET of
100 keV/μm (Fig. 3). The differences observed between IP and DP
survival with 100 keV/μm were statistically signiﬁcant for both U87
and LN18 but not T98G. This could be due to the low-dose
hypersensitive of T98G. The Wilcoxon Signed Ranks Test—exact
sig. (2-tailed) with a value of P < 0.05 was employed for this statis-
tical test. Figure 4 shows there was no PLDR with high-LET radi-
ation of 200 keV/μm, and the slope was reduced as most cells were
inactivated. There is an indication that the change in the slope of
the SF curve was dose dependent for repair processes for low-LET
radiation.
Note the observed trend for 200 keV/μm, that IP survival was
higher than DP, infers that there was no PLDR. The radiation-
induced damaged cells, when given the opportunity to repair before
dividing, were unable to do so. Hence, the survival of DP decreased,
Fig. 1. Cell survival curves of T98G (A), U87 (B) and LN18 (C), IP versus DP when irradiated with X-rays of LET 1.7 keV/
μm. IP = immediate plating, DP = 24 h delayed plating. Error bars indicate SD.
Fig. 2. Cell survival curves of T98G (A), U87 (B) and LN18 (C), IP versus DP when irradiated with 28Si (55 keV/μm). IP =
immediate plating, DP = 24 h delayed plating. Error bars indicate SD.
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indicating that the damaged cells were not able to repair and unable
to proliferate and were inactivated. None of the three GBM cell
lines could repair the complex damages induced by 200 keV/μm
radiation. When 24 h were allowed for the cells to repair, they were
unable to repair, and they died due to the severe radiation-induced
damage complexity. Hence, the surviving fractions of DP were
reduced.
X-ray potential lethal damage repair
Our results clearly displayed post radiation effects. IP cells were more
radiosensitive than the 24 h DP cells irradiated with X-rays of LET
1.7 keV/μm. X-ray PLDR increased for T98G and U87 at ≥ 4 Gy,
but for LN18 PLDR from ≥3 Gy onwards (Fig. 1 Panels A–C).
Charged ion potential lethal damage repair
There was apparent PLDR with LET of 55 keV/μm, minimal PLDR
for LET of 100 keV/μm and no PLDR for LET of 200 keV/μm.
For LET of 55 keV/μm, T98G and U87 PLDR started at >1 Gy
onwards. For LN18 cells, PLDR shows a consistent rise with
increase in dose (Fig. 2 Panels A–C). LET of 100 keV/μm showed
minimal PLDR for all three GBMs (Fig. 3 Panels A–C). There was
no PLDR detected in any GBM cell line with the high LET of
200 keV/μm (Fig. 4 Panels A–C).
DISCUSSION
The aim of this study was to quantify the ability of GBM cell lines
to repair PLD following charged ion irradiations with different levels
Fig. 4. Cell survival curves of T98G (A), U87 (B) and LN18 (C), IP versus DP when irradiated with 28Si (200 keV/μm).
IP = immediate plating, DP = 24 h delayed plating. Error bars indicate SD.
Fig. 3. Cell survival curves of T98G (A), U87 (B) and LN18 (C), IP versus DP when irradiated with 12C (100 keV/μm). IP =
immediate plating, DP = 24 h delayed plating. Error bars indicate SD.
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of LET in comparison with X-rays. GBM is known clinically to be
radioresistant and, in vitro, GBM cell lines have revealed large
PLDR with photon irradiation [41]. In addition, 9L gliosarcoma
have shown PLDR following irradiation with 12C ions [31].
Growth conditions for potential lethal damage repair
study
Plateau phase has been used as it has similar characteristics to
tumours in vivo, in which a large proportion of the tumour is in G1
or G0 phase [18–21, 30, 40, 42–44]. Furthermore, exponential
phase (log phase) culture has been shown to display lower PLDR
[24, 30]. Hahn et al. lists some of the post-irradiation conditions
that allow PLDR after X-ray irradiation: reduction in temperature;
growth under suboptimal conditions such as in plateau-phase cul-
tures or in situ hypoxia; and inhibition of protein synthesis [21].
Analogous to solid tumours, where hypoxic regions are present, a
lack of blood vessels, a low level of nutrients and an acidic extracel-
lular environment with high concentration of cellular waste products
after the ﬁrst irradiation may enable cells to repair instead of prolif-
erate (and thus promote PLDR) [21]. GBM is a known hypoxic
tumour. In this study, GBM cells were allowed to repair radiation
damage for 24 h instead of proliferating, by neither removing them
nor changing the medium. Twenty four hours delay was chosen to
ensure the PLDR had been completed, as has been researched by
Yashiro et al. [27], who found that at 18 h post irradiation, PLDR
was thought to be stable. Moreover, this also simulated a typical
clinical setting as radiotherapy is generally given on a daily basis.
Other studies have examined a limited number of dose points
[20, 31]. In this study, a wide-range of dose points (0.2, 0.25, 0.4,
0.5, 0.6, 0.75 and 0.8 Gy) were employed to determine low-dose
hypersensitivity (HRS), up to doses of 8 Gy. Moreover, Marchese
et al. report that ﬁtting DP results to SCs increases the accuracy of
the recovery ratio as compared with using individual single doses
[24]. Doses of >5 Gy with 12C (135 MeV/n, LET 100 keV/μm)
were not chosen for T98G as it was estimated to be highly toxic.
Similarly, doses of >4 Gy for U87 and LN18 were not used for fear
of ‘overkill’. More than 8 Gy for high-LET radiation was not prac-
tical as the large number of cells necessary to be used may have
given rise to statistical uncertainties (due to very low number of sur-
viving colonies versus number of cells inoculated).
Charged ion potential lethal damage repair and potential
lethal damage repair ratio
The majority of PLDR studies have been carried out using photons
(X- or γ-rays) [16–18, 20, 21, 43, 45] and other types of cell line.
We believe that this study of the PLDR relationship to the type of
ion species and the level of LET of the irradiation is the ﬁrst to be
performed on three different GBM strains. For charged particle
irradiation, Guichard et al. [32] reported that PLDR in EMT-6
(mouse mammary carcinoma) tumours irradiated with SOBP 4He
ions was similar to that observed with γ-irradiation. In addition,
Wheeler et al. [31] observed recovery of PLDR in 9L gliosarcoma
cells (in situ) that were stereotactically implanted into the left cere-
bral hemisphere of male Fisher 344 rats irradiated with a dose of
13.5 Gy at a dose rate of 10 Gy/min (using 400 MeV/nucleon 12C
ions (SOBP) with a median LET of ~40 keV/μm) in comparison
with X-rays at a dose rate of 2 Gy/min; the extent of recovery was
almost identical to that observed with X-rays. We concur with
Wheeler et al. as our irradiations with a LET of 55 keV/μm showed
evidence of PLDR. Moreover, the PLDR ratio demonstrated that,
with a LET of 100 keV/μm, there was minimal PLDR for the three
GBM cell lines. This suggests that with a LET of 100 keV/μm, low
doses were not sufﬁcient to produce irreparable damages, even
though it has been accepted that it is the optimal LET for produ-
cing a biological effect [46]. (At this density of ionization, the aver-
age separation between ionizing events approximately coincides
Table 2. T98G, U87 and LN18—LET of 1.7, 55, 100 and 200 keV/μm dose point PLDR ratioa
LET 1.7 keV/μm 55 keV/μm 100 keV/μm 200 keV/μm
GBM T98G U87 LN18 T98G U87 LN18 T98G U87 LN18 T98G U87 LN18
Dose Dose Dose Dose Dose
(Gy) (Gy) (Gy) (Gy) (Gy)
0.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00 1.00
0.50 0.88 1.40 1.05 0.25 1.03 0.90 1.19 0.20 1.10 1.15 0.20 1.36 0.20 0.99 0.87 0.95
1.00 0.77 1.13 0.98 0.50 0.95 1.02 1.24 0.40 1.08 1.24 0.40 1.08 0.40 0.95 0.86 0.93
2.00 0.87 1.30 0.96 0.75 0.89 1.00 1.23 0.80 1.22 1.15 0.80 1.18 0.60 0.71 0.65 0.97
3.00 0.99 1.04 1.16 1.00 0.85 1.06 1.24 1.20 1.25 1.07 1.20 1.17 1.00 0.83 0.84 0.93
4.00 1.23 0.87 1.51 2.00 1.07 1.22 1.33 2.40 0.88 1.13 2.40 1.13 2.00 0.79 0.97 0.88
6.00 3.01 1.85 2.38 4.00 2.64 1.91 2.05 4.80 0.75 1.06 3.60 1.18 4.00 1.00 0.99 0.87
8.00 21.00 4.72 5.21 6.00 2.56 3.95 8.10 6.00 1.00 0.29 0.68
aPLDR ratio = surviving fraction of delayed plating/surviving fraction of immediate plating (DP/IP). Ratio of ≤1 indicates no PLDR.
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with the diameter of a DNA double helix, i.e. 2 nm in width, and
has the highest probability of a single charged particle causing a
double-strand break). In contrast, irradiation with a LET of
200 keV/μm showed no PLDR for any of the three GBM cell lines.
Our results showed that a high LET of 200 keV/μm induced mostly
lethal damage in the GBM cells (such as local multiple damage sites
that are complicated and complex, and which, according to Ward, are
difﬁcult to repair to the original status or not reparable at all [47]).
X-ray potential lethal damage repair and potential lethal
damage repair ratio
From Table 2, it is intriguing to note that the X-ray PLDR ratio for
T98G increased by a factor of 1.2 with 4 Gy, 3.0 with 6 Gy and 21.0
with 8 Gy. This reveals the potential ineffectiveness of high doses of
irradiation for T98G types of tumour. It could be inferred that escal-
ating doses may not beneﬁt strains of GBM that exhibit low-dose
HRS. Our results showed that with T98G the PLDR ratio increased
with increasing dosage, but its known low-dose HRS GBM cell lines
[48] demonstrated no PLDR at doses below 2 Gy (Table 2 and
Fig. 1 Panel A). While GBMs are known radioresistant tumours,
our results concurred with Short et al. in that T98G and U87 dis-
played low-dose HRS to X-ray radiation. However, U87 cells only
exhibited low-dose HRS to doses of 0.25 Gy for LET 55 keV/μm
[48, 49]. Although, Short et al. report that low-dose HRS usually
occurs at doses <1 Gy with X-rays, our results showed PLDR up to
2 Gy, which could be due to the dose rate of 1 Gy/min (compared
with Short et al., who employed 0.2–0.4 Gy/min); the methods and
medium employed were also different. Low-dose HRS is common
in radioresistant glioma and is more marked in more radioresistant
cell lines [49]. Therefore, treating GBM with high doses for both
low- (X-rays) and high-LET radiation may result in an increase in
radioresistance, although the clinical outcome will obviously be dif-
ferent for both, assuming the high-LET radiation hits the GBM
cells.
The X-ray PLDR ratios at 6 Gy were similar to the results of
Weichselbaum et al. [3, 20], who reported a PLDR ratio of 2.8 at
7 Gy (based on a single dose point) for GBM; our results showed a
similar but varied range of 1.85 to 3.01 at 6 Gy (Table 2—LET
1.7 keV/μm, X-ray column).
Potential lethal damage repair RBE10 and RBE2 Gy, α, β
and α/β
From Table 1, comparing RBED10 and RBED2 Gy, a distinct
difference was found with X-ray RBE10. While DP RBE10 decreased,
DP RBE2Gy increased for T98G and U87, and this indicates that
T98G and U87 exhibited the presence of low-dose HRS to X-rays
[48, 49]. RBE2 Gy could be used as a good indicator for intrinsic
tumour cell radiosensitivity, especially with high-LET radiation as it
can demonstrate the effect for typical clinical 2 Gy daily treatments.
There was a distinct difference in PLDR α values between
X-rays and ion radiations; X-ray PLDR α values showed a deﬁnite
increase in all three GBM strains but decrease with increasing
LET < 200 keV/μm. This differs from the ﬁndings of Malaise et al.
[50], who reported that PLDR led to a decrease in α value in their
study of published data that were comprised of both ﬁbroblast and
tumour-derived cells but did not include GBM cell lines. Their
report suggested that a link may exist between the repair capacity
and the intrinsic radiosensitivity [50]. The X-ray β-value was higher
at IP, which concurs with Malaise et al. [50]. Generally, the trend
for PLDR β-value decreased as LET increased. From Table 1,
T98G and LN18 DP α/β ratios increased signiﬁcantly with X-rays
(LET 1.7 keV/μm) and 28Si-ions (LET 200 keV/μm). For U87 DP,
the α/β ratio increase was observed for X-rays (LET 1.7 keV/μm)
and for ions of up to ~100 keV/μm LET, but not 200 keV/μm.
LN18 was the only GBM cell line that had an α/β ratio in the hun-
dreds with LET 200 keV/μm and decreased to the order of tens at
LET of <200 keV/μm. Both T98G and U87 showed peak α/β
ratios at LET 100 and 200 keV/μm, respectively. For LN18, the α/
β ratio increased as the LET increased. The increase in the α/β
ratio for high-LET radiation may imply that fractionation effects are
not crucial, but this needs to be conﬁrmed with in vivo experiments.
This observation supports the increasing use of hypofractionationed
regimens for the treatment of tumours with high-LET radiation
therapy. However, further in-depth studies are required.
Our results concurred with Weichselbaum et al. [3]; they indi-
cated that the capacity for PLDR is a cellular repair characteristic
that may differ between cell types, and also that the more radioresis-
tant the tumour, the higher the PLDR. This inherent cellular radio-
resistance in GBM may play an important factor in clinical
radiocurability. PLDR in GBM may be responsible for failure in
radiotherapy especially with X-ray treatment [19, 49]. Even with a
high LET of 100 keV/μm, these slow-growing cells are able to
induce PLDR. Our results show that at low LET, GBM PLDR is
dose dependent [43], except for in T98G cells, which demonstrate
HRS [49]. Conversely, Marchese et al. [24] describe no correlation
between PLDR and in vitro radiosensitivity or clinical radiosensitiv-
ity of the tumour type.
These results demonstrated that GBM PLDR depended on LET
and on the HRS of the cells. Even though charged ion therapy may
be a prospective candidate treatment option for improving and pro-
gressing the treatment of GBM, our results showed that GBM cells
were able to repair damage induced by high-LET charged ion radi-
ation, even up to 100 keV/μm. In conclusion, our results indicated
that PLDR of GBM is dependent on LET, dose, and cell strain. The
intrinsic radiosensitivity of GBMs based on their genetic alterations
will need to be examined in future work.
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